Linear irregular or arborizing vessels and ulceration were more often seen on high-risk tumors

American Academy of Dermatology survey reveals one-third of U.S. adults reported past-year sunburn

The expanded indication is for children ages 2 to 11 years who remain symptomatic despite histamine-1 antihistamine treatment

Short- or long-term risk for adverse corticosteroid effects did not increase with multiple intramuscular triamcinolone injections

Discrimination modest, but model demonstrated excellent calibration across predictor subgroups

BMI, diabetes, biologic use, smoking, URTI, nonstandard medication were identified as independent risk factors and included in model

Higher risk seen with increasing disease severity

Models built based on routine electronic health record data

In treating atopic dermatitis, the question is not only how quickly a patient can improve, but how to build a plan that respects the...

Findings presented at AAD26 highlight rapid onset and deepening responses through week 24

A late-March formulary update may change how often tirbanibulin is a realistic option in clinic.

Increasing birth length positively associated with atopic dermatitis by age 3 years, while inverse association seen for short birth length

Guidelines also developed for medical management of pediatric atopic dermatitis, including 27 evidence-based recommendations

Increased mortality seen with primary tumor location in head and neck site; mortality reduced for location in upper limb/shoulder and lower limb/hip

Definitions developed for low disease activity, very low disease activity, remission in atopic dermatitis

An oral TYK2 inhibitor now carries an indication across both skin and joint disease

Atopic dermatitis rarely behaves the same way twice, which means the real work of treating it begins in everything we don’t immediately see.

Sometimes the smallest structure in the exam, the nail, offers some of the clearest clues to what’s really going on beneath the surface.

Major criteria for vitiligo include spread or active disease, involvement of highly visible or high-impact areas, psychological distress

Phase 3 studies show the highly selective oral tyrosine kinase 2 inhibitor provides rapid, durable skin improvement

Benefits include total and facial repigmentation in patients 12 years and older versus placebo

Ixekizumab plus tirzepatide tied to simultaneous benefit of American College of Rheumatology 50 percent improvement and weight reduction